[Progress in cancer immunotherapy]

MMW Fortschr Med. 2017 Aug;159(14):48-53. doi: 10.1007/s15006-017-9949-y.
[Article in German]
No abstract available

Keywords: CTLC-4; Cancer; PD-L1; immunotherapy.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antigen-Presenting Cells / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • CTLA-4 Antigen / antagonists & inhibitors
  • Cell Death
  • Dendritic Cells / immunology
  • Immunotherapy / adverse effects
  • Immunotherapy / methods*
  • Ipilimumab / therapeutic use
  • Lymph Nodes / immunology
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Programmed Cell Death 1 Receptor / physiology
  • Receptors, Antigen, T-Cell / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CTLA-4 Antigen
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Antigen, T-Cell
  • tremelimumab